CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Treprostinil sodium

Last Updated: July 14, 2004
Result type: Reports
Project Number: S0011
Product Line: Common Drug Review

Generic Name: Treprostinil sodium

Brand Name: Remodulin

Manufacturer: Northern Therapeutics Inc.

Indications: Pulmonary arterial hypertension (NYHA Class III and IV patients)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: November 17, 2004

Recommendation Type: Do not list